You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧翔藥業(603229.SH):子公司擬投資新建國際化製劑產業基地項目(一期)
格隆匯 03-26 15:37

格隆匯 3 月 26日丨奧翔藥業(603229.SH)公佈,浙江麒正藥業有限公司(“麒正藥業”)為公司的全資子公司。進一步擴大公司規模,加快向製劑領域發展提升公司產品的附加值,實現中間體+特色原料藥+製劑的一體化升級麒正藥業擬投資新建“國際化製劑產業基地項目,上述項目將分二期實施,此次麒正藥業投資新建國際化製劑產業基地項目(一期)(“該項目”),該項目預計投資49100萬元人民幣。

項目位於台州灣建設2項目新建8個產品的生產車間(廠房1、廠房2)及配套的輔助廠房劑庫、廢水處理站。項目建成後年產2.3億片高活性靶向抗腫瘤片劑/膠囊,34億片普通口服固體片劑/膠囊。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account